1
|
Hamshaw I, Ellahouny Y, Malusickis A, Newman L, Ortiz-Jacobs D, Mueller A. The role of PKC and PKD in CXCL12 and CXCL13 directed malignant melanoma and acute monocytic leukemic cancer cell migration. Cell Signal 2024; 113:110966. [PMID: 37949381 DOI: 10.1016/j.cellsig.2023.110966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Revised: 10/03/2023] [Accepted: 11/05/2023] [Indexed: 11/12/2023]
Abstract
Cancer metastasis is the leading cause of cancer related mortality. Chemokine receptors and proteins in their downstream signalling axis represent desirable therapeutic targets for the prevention of metastasis. Despite this, current therapeutics have experienced limited success in clinical trials due to a lack of insight into the downstream signalling pathway of specific chemokine receptor cascades in different tumours. In this study, we investigated the role of protein kinase C (PKC) and protein kinase D (PKD) in CXCL12 and CXCL13 stimulated SK-MEL-28 (malignant melanoma) and THP-1 (acute monocytic leukaemia) cell migration. While PKC and PKD had no active role in CXCL12 or CXCL13 stimulated THP-1 cell migration, PKC and PKD inhibition reduced CXCL12 stimulated migration and caused profound effects upon the cytoskeleton of SK-MEL-28 cells. Furthermore, only PKC and not PKD inhibition reduced CXCL13 stimulated migration in SK-MEL-28 cells however PKC inhibition failed to stimulate any changes to the actin cytoskeleton. These findings indicate that PKC inhibitors would be a useful therapeutic for the prevention of both CXCL12 and CXCL13 stimulated migration and PKD inhibitors for CXCL12 stimulated migration in malignant melanoma.
Collapse
Affiliation(s)
- Isabel Hamshaw
- School of Pharmacy, University of East Anglia, Norwich NR4 7TJ, UK
| | | | - Artur Malusickis
- School of Pharmacy, University of East Anglia, Norwich NR4 7TJ, UK
| | - Lia Newman
- School of Pharmacy, University of East Anglia, Norwich NR4 7TJ, UK
| | | | - Anja Mueller
- School of Pharmacy, University of East Anglia, Norwich NR4 7TJ, UK.
| |
Collapse
|
2
|
Hamshaw I, Straube A, Stark R, Baxter L, Alam MT, Wever WJ, Yin J, Yue Y, Pinton P, Sen A, Ferguson GD, Blanks AM. PGF 2α induces a pro-labour phenotypical switch in human myometrial cells that can be inhibited with PGF 2α receptor antagonists. Front Pharmacol 2023; 14:1285779. [PMID: 38155905 PMCID: PMC10752971 DOI: 10.3389/fphar.2023.1285779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Accepted: 11/21/2023] [Indexed: 12/30/2023] Open
Abstract
Preterm birth is the leading cause of infant morbidity and mortality. There has been an interest in developing prostaglandin F2α (PGF2α) antagonists as a new treatment for preterm birth, although much of the rationale for their use is based on studies in rodents where PGF2α initiates labour by regressing the corpus luteum and reducing systemic progesterone concentrations. How PGF2α antagonism would act in humans who do not have a fall in systemic progesterone remains unclear. One possibility, in addition to an acute stimulation of contractions, is a direct alteration of the myometrial smooth muscle cell state towards a pro-labour phenotype. In this study, we developed an immortalised myometrial cell line, MYLA, derived from myometrial tissue obtained from a pregnant, non-labouring patient, as well as a novel class of PGF2α receptor (FP) antagonist. We verified the functionality of the cell line by stimulation with PGF2α, resulting in Gαq-specific coupling and Ca2+ release, which were inhibited by FP antagonism. Compared to four published FP receptor antagonists, the novel FP antagonist N582707 was the most potent compound [Fmax 7.67 ± 0.63 (IC50 21.26 nM), AUC 7.30 ± 0.32 (IC50 50.43 nM), and frequency of Ca2+ oscillations 7.66 ± 0.41 (IC50 22.15 nM)]. RNA-sequencing of the MYLA cell line at 1, 3, 6, 12, 24, and 48 h post PGF2α treatment revealed a transforming phenotype from a fibroblastic to smooth muscle mRNA profile. PGF2α treatment increased the expression of MYLK, CALD1, and CNN1 as well as the pro-labour genes OXTR, IL6, and IL11, which were inhibited by FP antagonism. Concomitant with the inhibition of a smooth muscle, pro-labour transition, FP antagonism increased the expression of the fibroblast marker genes DCN, FBLN1, and PDGFRA. Our findings suggest that in addition to the well-described acute contractile effect, PGF2α transforms myometrial smooth muscle cells from a myofibroblast to a smooth muscle, pro-labour-like state and that the novel compound N582707 has the potential for prophylactic use in preterm labour management beyond its use as an acute tocolytic drug.
Collapse
Affiliation(s)
- Isabel Hamshaw
- Clinical Science Research Laboratories, Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, United Kingdom
| | - Anne Straube
- Centre for Mechanochemical Cell Biology, Division of Biomedical Sciences, University of Warwick, Coventry, United Kingdom
| | - Richard Stark
- Bioinformatics RTP, Warwick Medical School, University of Warwick, Coventry, United Kingdom
| | - Laura Baxter
- Bioinformatics RTP, Warwick Medical School, University of Warwick, Coventry, United Kingdom
| | - Mohammad T. Alam
- Bioinformatics RTP, Warwick Medical School, University of Warwick, Coventry, United Kingdom
| | | | - Jun Yin
- Ferring Research Institute Inc., San Diego, United Kingdom
| | - Yong Yue
- Ferring Research Institute Inc., San Diego, United Kingdom
| | - Philippe Pinton
- Ferring Research Institute Inc., San Diego, United Kingdom
- Ferring Pharmaceuticals, International PharmaScience Center, Kastrup, Denmark
| | - Aritro Sen
- Ferring Research Institute Inc., San Diego, United Kingdom
| | | | - Andrew M. Blanks
- Clinical Science Research Laboratories, Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, United Kingdom
- Centre for Mechanochemical Cell Biology, Division of Biomedical Sciences, University of Warwick, Coventry, United Kingdom
| |
Collapse
|
3
|
Hamshaw I, Cominetti MMD, Lai WY, Searcey M, Mueller A. The development of potent, competitive CXCR4 antagonists for the prevention of cancer metastasis. Biochem Pharmacol 2023; 218:115921. [PMID: 37956893 DOI: 10.1016/j.bcp.2023.115921] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Revised: 11/09/2023] [Accepted: 11/10/2023] [Indexed: 11/19/2023]
Abstract
Cancer metastasis is the cause of up to 90 % of cancer related mortality. The CXCR4 receptor and its cognate ligand, CXCL12, have major roles in enabling cancer metastasis and consequently, the CXCR4 receptor has become an attractive therapeutic target for the prevention of metastasis. Despite this, CXCR4 antagonists have had limited success in clinical trials due to cellular toxicity and poor stability and efficacy. In this study, we developed a novel, competitive CXCR4 antagonist (IS4) that through copper-catalysed-azide-alkyne-cycloaddition can be clicked to other chemical moieties such as fluorescent dyes (IS4-FAM) for CXCR4-based imaging. We determined that these CXCR4 antagonists were non-toxic and could be used to specifically label the CXCR4 receptor. Furthermore, IS4 and IS4-FAM inhibited CXCL12-stimulated cancer cell migration and Ca2+ release in both adherent and suspension cell lines with similar or improved potency as compared to two literature CXCR4 antagonists. Our results highlight the potential of IS4 and IS4-FAM as research tools and as potent CXCR4 antagonists for the prevention of metastasis.
Collapse
Affiliation(s)
- Isabel Hamshaw
- School of Pharmacy, University of East Anglia, Norwich, UK
| | | | - Wing-Yee Lai
- School of Pharmacy, University of East Anglia, Norwich, UK
| | - Mark Searcey
- School of Pharmacy, University of East Anglia, Norwich, UK
| | - Anja Mueller
- School of Pharmacy, University of East Anglia, Norwich, UK.
| |
Collapse
|